E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Preservation of beta (β)-islet cell function in patients newly diagnosed with Type 1 Diabetes |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045228 |
E.1.2 | Term | Type I diabetes mellitus |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the effect of NI-0401 on the preservation of β-islet cell function as demonstrated by the AUC of stimulated C-peptide release. To investigate the safety of three dose regimens of NI-0401 in patients with newly diagnosed T1D. |
|
E.2.2 | Secondary objectives of the trial |
To investigate the effect of therapy with NI-0401 on the metabolic control of T1D demonstrated by regular measurement of: HbA1c over timeo; Insulin requirements over time; Average glucose measurements over time; Episodes of hyper and hypoglycemia. To assess the pharmacodynamic and immunomodulatory effect of NI-0401 as demonstrated by regular measurement of: extent and duration of CD3-TCR modulation; number of circulating leucocytes and leucocyte subsets; serum pro and anti inflammatory cytokines; mRNA expression in leucocyteso plasma concentration of diabetes associated auto antibodies. To assess the plasma pharmacokinetics of NI-0401. To assess the potential for emergent anti-drug antibody and its effect on the efficacy and safety of NI-0401. To assess the safety and efficacy of a single course vs. two courses of NI-0401 in patients with newly diagnosed T1D. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients with T1D diagnosed according to the American Diabetes Association 2003 criteria 2. Date of diagnosis within 12 weeks prior to the first dose of study drug 3. Evidence of diabetes associated autoantibodies including at least one of the following: Glutamic acid decarboxylase 65 antibody (GADA); Protein tyrosine phosphatase-like protein IA-2 (IA-2A); Islet cell antibody (ICA) 4. Male or Female patients aged ≥ 12 and ≤ 40 years 5. Fasting C-peptide level ³ 0.25 nmol/l 6. Effective written informed consent 7. EBV-IgG antibody positive 8. Willing to avoid pregnancy during trial participation. |
|
E.4 | Principal exclusion criteria |
1. Pregnant or lactating women 2. Any medical condition that, in the opinion of the investigator, would interfere with safe completion of the trial or that would prevent patients from providing informed consent. 3. Known or previous diagnosis of malignancies. 4. Current active infections: Any current active infection; Active tuberculosis (TB) within 12 months of study entry or currently undergoingtreatment for TB; Evidence of active or chronic hepatitis including hepatitis B or C; History of or currently active primary or secondary immunodeficiency including known history of HIV infection; Patients with detectable EBV/CMV viral DNA in plasma. 5. Current active alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to baseline. 6. A history of hypersensitivity or allergy to any components of the study regimen. 7. Previous treatment with any cell-depleting therapies, including investigational agents (e.g. alemtuzumab, anti-CD3, anti-CD4, anti-CD5, anti-CD11a, anti-CD19, anti-CD22, anti-BLys/BAFF, or anti-CD20). 8. Treatment with another investigational drug within 3 months or five half-lives of the investigational drug prior to baseline, whichever is longer. 9. Receipt of or need for a live vaccine within 8 weeks prior to and following receipt of study drug treatment. 10. Laboratory tests; WBC count < 2500 x 106/l; CD4 lymphocyte count < 500 x 106/l; ALT > 2 ULN. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The mean change from baseline in the AUC of stimulated C-Peptide at Month 6 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 57 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The point at which all patients have completed the month 24 visit (or prematurely discontinued) and the database is locked for the Month 24 analysis |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |